Another study found that inhibition of nuclear trafficking via XPO1 leads to a synthetic lethal effect on KRAS-mutant cancer cells through the inhibition of transcription factor NF-κB, introducing a targetable notion for NSCLC therapies [85]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.